Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00420888
Status:
COMPLETED
Last Update Posted:
2015-07-22
First Post:
2007-01-09
Brief Title:
ABR-217620Naptumomab Estafenatox With Interferon-alpha IFN-alpha Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
Sponsor:
Organization:
Active Biotech AB
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
526
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: